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BACKGROUND: The relationship between risk factor or
biomarker trajectories and contemporaneous short-term
clinical outcomes is poorly understood. In diabetes pa-
tients, it is unknown whether hemoglobin A1c (HbA1c)
trajectories are associated with clinical outcomes and
can inform care in scenarios in which a single HbA1c is
uninformative, for example, after a diagnosis of coronary
artery disease (CAD).
OBJECTIVE: To compare associations of HbA1c trajecto-
ries and single HbA1c values with short-termmortality in
diabetes patients evaluated for CAD
DESIGN: Retrospective observational cohort study
PARTICIPANTS: Diabetes patients (n = 7780) with and
without angiographically defined CAD
MAIN MEASURES: We used joint latent class mixed
models to simultaneously fit HbA1c trajectories and esti-
mate association with 2-year mortality after cardiac cath-
eterization, adjusting for clinical and demographic
covariates.
KEY RESULTS: Three HBA1c trajectory classes were
identified: individuals with stable glycemia (class A; n =
6934 [89%]; mean baseline HbA1c 6.9%), with declining
HbA1c (class B; n = 364 [4.7%]; mean baseline HbA1c
11.6%), and with increasing HbA1c (class C; n = 482
[6.2%]; mean baseline HbA1c 8.5%). HbA1c trajectory
class was associated with adjusted 2-year mortality
(3.0% [95%CI 2.8, 3.2] for class A, 3.1% [2.1, 4.2] for class
B, and 4.2% [3.4, 4.9] for class C; global P = 0.047, P =
0.03 comparing classes A and C, P > 0.05 for other
pairwise comparisons). Baseline HbA1c was not associat-
ed with 2-year mortality (P = 0.85; hazard ratios 1.01
[0.96, 1.06] and 1.02 [0.95, 1.10] for HbA1c 7–9% and ≥
9%, respectively, relative to HbA1c < 7%). The association
INTRODUCTION
In the era of electronic health records (EHR), repeated mea-
surements of biomarkers and disease risk factors are readily
available, but most clinical guidelines recommend treatment
decision-making based on solitary measurements. While
guidelines for common chronic diseases such as diabetes and
hypertension base recommendations on the last available val-
ue,1, 2 there may be clinical scenarios in which the last avail-
able measurement is a poor predictor of clinical outcomes. In
such scenarios, the integration of serial biomarker measure-
ments into trajectories may be clinically informative. That is,
the biomarker trajectory may reflect risk of an important
clinical outcome, irrespective of a causal mechanism. Howev-
er, the relationship between risk factor or biomarker trajecto-
ries and clinical outcomes remains poorly understood.
Diabetes mellitus, a disease in which a biomarker—
hemoglobin A1c (HbA1c)—is measured serially to monitor
glycemic control, provides a model clinical context in which
to evaluate differential associations of a single HbA1c value
and longitudinal trajectories with clinical outcomes. HbA1c is
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between HbA1c trajectories and mortality did not differ 
between those with and without CAD (interaction P = 0.1).  
CONCLUSIONS: In clinical settings where single HbA1c 
measurements provide limited information, HbA1c trajec-
tories may help stratify risk of complications in diabetes 
patients. Joint latent class modeling provides a generaliz-
able approach to examining relationships between bio-
marker trajectories and clinical outcomes in the era of 
near-universal adoption of electronic health records.
KEY WORDS: diabetes; hemoglobin A1c trajectory; cardiovascular disease; 
mortality.
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a predictor of diabetes complications and mortality,1, 3–10 and
professional society guidelines recommend serial HbA1c
monitoring. However, the guidelines do not offer diabetes
management recommendations based on HbA1c trajectory.1,
11 Thus, clinical providers typically adjust diabetes treatment
based on the last available HbA1c measurement, even though
that single value does not predict meaningful clinical out-
comes in certain clinical settings.
One clinical scenario in which the last available
HbA1c measurement is not associated with short-term
clinical outcomes occurs after myocardial infarction (MI)
or percutaneous coronary intervention (PCI) for coronary
artery disease (CAD).12–15 In this study, we used a real-
world cohort of diabetes patients undergoing diagnostic
evaluation for CAD to identify glycemic control trajec-
tories, describe the characteristics of patients with dis-
tinct HbA1c trajectories, and compare the associations




We included all US veterans diagnosed with diabetes
prior to October 2015 who underwent coronary angiog-
raphy for indications related to CAD in the US Veterans
Affairs (VA) healthcare system between October 2005
and September 2016. Data were recorded in a standard-
ized fashion through the VA Clinical Assessment,
Reporting, and Tracking Program (CART).16 We identi-
fied diabetes patients as those with at least one ICD-9
diabetes diagnosis code for inpatient encounters or at
least two ICD-9 diabetes codes for outpatient visits on
separate days, excluding codes for secondary diagnosis
of diabetes.17 To avoid confounding by diabetes dura-
tion, we included individuals who met the diabetes
definition within 24 months of their index cardiac cath-
eterization and excluded those who had a qualifying
diabetes diagnosis code more than 2 years prior to
catheterization or were newly diagnosed with diabetes
at the time of catheterization. To be included, partici-
pants had to have at least 6 months of records in the
VA preceding index catheterization, at least one HbA1c
measurement in the 24 months preceding angiography,
and at least one HbA1c measurement during follow-up.
We included individuals whose indication for angiogra-
phy was related to CAD (chest pain, stable angina,
positive functional study, or ischemic heart disease).
For patients with multiple angiographies, we used
HbA1c values after their first cardiac catheterization
for this study and excluded patients with a prior MI or
coronary revascularization. Loss to follow-up was de-
fined as those with fewer than 3 months of follow-up
time (without an outcome event) after catheterization.
The Colorado Multiple Institution Review Board provid-
ed human subjects oversight and approval.
Exposures, Outcomes, and Covariates
The primary exposure was HbA1c trajectory during follow-up
after cardiac catheterization, using the last HbA1c measure-
ment before catheterization and all HbA1c measurements up
to 2 years after catheterization. The primary outcome was 2-
year all-cause mortality measured using VA vital status data.
All multivariable models were adjusted for demographics
(age, sex, race), cardiovascular risk factors (hypertension,
hyperlipidemia, Framingham risk score, smoking status, body
mass index), comorbidities (heart failure [HF], chronic ob-
structive pulmonary disease, post-traumatic stress disorder,
peripheral artery disease, chronic kidney disease, dialysis,
depression), post-angiography revascularization (none, PCI,
coronary artery bypass graft), diabetes duration, and medica-
tion adherence at baseline for cardioprotective medications
(HMG-CoA reductase inhibitors [statins], angiotensin-
converting enzyme inhibitors [ACEi] or angiotensin receptor
blockers [ARB], and beta-blockers) based on proportion of
days covered (PDC) dichotomized at a threshold of ≥ 0.8.18 In
secondary analyses, we included CAD burden as a covariate
and in an interaction term with HbA1c trajectory using stan-
dard definitions of flow-limiting stenosis19 (Online Supple-
ment, Table S7). All variables included in multivariable
models are described in the Online Supplement (Table S7).
Statistical Analyses
We opted to model HbA1c trajectories and associations
with mortality jointly using joint latent class mixed
models,20, 21 overcoming limitations of the two-stage ap-
proach to trajectory analysis used in prior studies of dia-
betes patients,22–24 particularly that the two-stage study
design precludes estimation of contemporaneous associa-
tions between trajectories and outcomes.25, 26 Joint latent
class modeling provides an alternative approach to trajec-
tory analysis in which the risk factor trajectories and their
associations with an outcome can be estimated contempo-
raneously.20, 21 The rationale for the study design is de-
scribed in detail in the Online Supplement.
We performed the analyses in three steps. First, we fit a
series of latent class trajectory models to determine the func-
tional form of time and number of latent classes that best fit the
data.25, 26 We used Bayes information criteria (BIC) as the
primary measure of model fit, and secondarily assessed the
mean posterior probability of class membership across classes.
Models with a third-degree fixed effect for time, a second-
degree random time effect, and three latent HbA1c trajectory
classes with an autoregressive covariance structure to account
for correlation between repeated HbA1c measurements best fit
the data. Details of model selection are available in the Online
Supplement. As a sensitivity analysis of the trajectory models,
we verified that a three-trajectory model best fit the data after
limiting the sample to individuals using at least one diabetes
medication at baseline (Fig. S1).
The second step in the analysis was to compare patient-level
demographics, cardiovascular risk factors, diabetes-related
variables, and other covariates across HbA1c trajectory clas-
ses. We used chi-square tests for categorical data and Kruskal-
Wallis tests for continuous or ordinal data to compare variables
across HbA1c trajectory classes. The third step in the analysis
was to test associations between HbA1c trajectory classes and
mortality using joint latent class mixed models (R package
lcmm). This approach jointly identifies subgroups of patients
with different HbA1c trajectories after index catheterization
and estimates associations with mortality contemporaneous-
ly.20, 21 For the joint latent class survival model, class-specific
baseline mortality risk was modeled with a Weibull distribu-
tion, and the effects of covariates were assumed constant over
time. Finally, we used an omnibus interaction test to assess
whether HbA1c trajectory classes and their associations with
mortality varied across levels of CAD burden. As a sensitivity
analysis, we repeated the primary analyses in participants
without HF at baseline.
We also performed an exploratory analysis comparing dia-
betes medication prescriptions and adherence across individ-
uals in different HbA1c trajectory classes. Based on prescrip-
tion drug fills in the VA at baseline and 0–6, 6–12, and 12–
24 months after catheterization, individuals were classified as
being prescribed metformin, sulfonylureas, insulin, or other
diabetes medication classes. We compared the classes of dia-
betes medications prescribed and the number of distinct med-
ication classes used for each individual during each of the time
intervals. For adherence, we compared PDC (dichotomized at
0.8) for ACEi/ARB, beta-blockers, statins, sulfonylureas, and
metformin at 12 months after cardiac catheterization among
individuals who had survived for a year.
All analyses were performed in R (version 3.1, R Founda-
tion for Statistical Computing, Vienna, Austria), and statistical
code is available upon request.
RESULTS
We studied 7780 diabetes patients with a mean diabetes dura-
tion of 1.1 years at the time of cardiac catheterization. Of these,
7492 (96%) were men, 6141 (79%) were white, and their
average age was 62 years. The majority of participants had
obstructive CAD on the index catheterization (62%), while
20% had non-obstructive CAD, and 18% had no CAD. De-
mographic, comorbidity, and treatment-related variables for
the full study cohort are summarized in Table 1. Participants
had a median of 2 HbA1c measurements in the first 6 months
of follow-up and 5 over the 2-year follow-up period
(Table S8).
Joint latent class mixed models with three HbA1c trajectory
classes best fit the data: individuals with stable glycemia (class
A, n = 6934, 89%), individuals with a decline in HbA1c after
catheterization (class B, n = 364, 4.7%), and individuals with
an increase in HbA1c after catheterization (class C, n = 482,
6.2%) (Fig. 1). Mean HbA1c at the time of catheterization was
highest in class B (11.6%), lowest in class A (6.9%), and
intermediate in class C (8.5%) (Table 1). By 6 months after
cardiac catheterization, class C individuals had the highest
predicted HbA1c in the trajectory model (9.6% [95% CI 9.3,
9.9] for class C, 8.8% [8.5, 9.1] for class B, and 7.0% [6.9, 7.1]
for class A; Fig. 1). Compared to class B and class C individ-
uals, those in class Awere older on average, more likely to be
white, less likely to have HF, had the highest Framingham
cardiovascular risk score on average, and were more likely to
be adherent to cardioprotective medications at baseline
(Table 1).
Crude mortality rates across HbA1c trajectory classes were
4.3% in class A, 4.7% in class B, and 5.0% in class C. Crude 2-
year mortality based on HbA1c values, as opposed to trajec-
tory classes, was higher in individuals with HbA1c ≥ 9% than
in those with HbA1c < 7% or 7–9%, based on a single baseline
measurement or based on the mean of all HbA1c measure-
ments over 12 or 24 months of follow-up after cardiac cathe-
terization (Table S9). In multivariable joint latent class mixed
models, adjusted 2-year mortality differed across trajectory
classes (adjusted mortality rate of 3.0% [95% CI 2.8, 3.2] in
class A, 3.1% [95% CI 2.1, 4.2] in class B, and 4.2% [95% CI
3.4, 4.9] in class C; P = 0.047 for difference between classes;
Fig. 2a). Adjusted mortality differed significantly between
classes A and C (P = 0.03) but not between classes A and B
(P = 0.9) or between classes B and C (P = 0.5) (Fig. 2a). In
identical multivariable Cox proportional hazard models, base-
line HbA1c was not associated with 2-year mortality (Table 2).
The HbA1c trajectory classes observed were similar among
participants without HF at baseline compared to the full study
sample (Fig. S2). Among those without HF, the predicted
survival probability curves diverged initially between classes
A and C (adjusted 1-year mortality of 1.47% in class A vs
2.37% in class C) but came together at two years resulting in a
non-significant association between trajectory class and 2-year
mortality (Fig. S2, P = 0.95).
The association between HbA1c trajectory class and
mortality did not differ between those with no CAD,
non-obstructive CAD, and obstructive CAD (interaction
P = 0.1). Mortality events were less common among
those with no CAD or non-obstructive CAD than in
those with obstructive CAD such that the joint model
results were driven by those with obstructive CAD.
Among individuals with obstructive CAD, variation in
baseline clinical characteristics across trajectory classes
was similar to that observed for the full study popula-
tion (Table S10), and mortality differed across trajectory
classes in multivariable joint latent class mixed models
(adjusted mortality rate of 3.8% [95% CI 3.5, 4.1] in
class A, 4.9% [95% CI 3.6, 6.2] in class B, and 6.1%
[95% CI 4.9, 7.2] in class C; P = 0.039 for difference
between classes; Fig. 2b). Mortality differed between
classes A and C (P = 0.04) but not between classes A
and B (P = 1.0) or between classes B and C (P = 1.0)
(Fig. 2b).
In an exploratory analysis of diabetes medication prescrip-
tions, individuals in class A were more likely to be on no
medications (Fig. 3a, Table S11) and were less likely to be
prescribed insulin (Fig. 3b, Table S12) across all time points
examined. Individuals in HbA1c trajectory classes B and C
were similar with regard to the number of diabetes medica-
tions and medication classes prescribed at baseline and across
all timepoints during follow-up (Fig. 3a, b, Tables S11 and
S12). Adherence to cardioprotective medications was lower in
all three-trajectory classes at 12 months after cardiac catheter-
ization than at baseline, but the relative proportions of adher-
ence between classes A, B, and C were similar at baseline
(Table 1) and 12 months (Table S13). Individuals in class A
had higher adherence to sulfonylureas and metformin than
those in classes B and C at 12 months after catheterization
(Table S13). Sulfonylurea adherence was higher in class C
individuals than in class B, while metformin adherence was
higher in class B than in class C (Table S13). Crude 2-year
mortality was numerically higher in individuals with lower
Table 1 Characteristics of All Study Participants and Stratified by Hemoglobin A1c (HbA1c) Trajectory Class After Cardiac Catheterization
All participants Hemoglobin A1c trajectory class P value
Class A Class B Class C
n = 7780 n = 6934 n = 364 n = 482
Age (years), mean (SD) 61.9 (8.3) 62.3 (8.2) 58.4 (8) 58.1 (8) < 0.0001
Male, n (%) 7492 (96.3) 6683 (96.4) 347 (95.3) 462 (95.9) 0.51
Race, n (%) < 0.0001
White 6141 (78.9) 5545 (80) 255 (70.1) 341 (70.7)
Black 1426 (18.3) 1200 (17.3) 99 (27.2) 127 (26.3)
Other 213 (2.7) 189 (2.7) 10 (2.7) 14 (2.9)
Diabetes duration (years), mean (SD) 1.1 (0.6) 1.1 (0.6) 1 (0.6) 1.2 (0.5) < 0.0001
Baseline HbA1c (%), mean (SD) 7.2 (1.5) 6.9 (1.0) 11.6 (1.6) 8.5 (1.6) < 0.0001
Family History of CAD, n (%) 1398 (18) 1235 (17.8) 58 (15.9) 105 (21.8) 0.05
Tobacco, n (%) 4367 (56.1) 3889 (56.1) 198 (54.4) 280 (58.1) 0.55
Hypertension, n (%) 7060 (90.7) 6296 (90.8) 322 (88.5) 442 (91.7) 0.25
Hyperlipidemia, n (%) 6819 (87.6) 6093 (87.9) 312 (85.7) 414 (85.9) 0.23
BMI (kg/m2), mean (SD) 33.1 (6.2) 33 (6.2) 32.9 (6.6) 33.7 (6.6) 0.13
Framingham risk score, mean (SD) 19.7 (10.9) 19.8 (10.9) 19.4 (11.3) 18.7 (10.7) 0.03
PAD, n (%) 1013 (13) 912 (13.2) 49 (13.5) 52 (10.8) 0.32
HF, n (%) 1086 (14) 925 (13.3) 72 (19.8) 89 (18.5) < 0.0001
COPD, n (%) 1264 (16.2) 1149 (16.6) 52 (14.3) 63 (13.1) 0.08
CKD, n (%) 1053 (13.5) 927 (13.4) 57 (15.7) 69 (14.3) 0.40
Dialysis, n (%) 112 (1.4) 105 (1.5) 4 (1.1) 3 (0.6) 0.24
Depression, n (%) 2414 (31) 2130 (30.7) 115 (31.6) 169 (35.1) 0.13
PTSD, n (%) 1396 (17.9) 1257 (18.1) 56 (15.4) 83 (17.2) 0.38
Presentation, n (%) 0.26
Stable angina 216 (2.8) 198 (2.9) 9 (2.5) 9 (1.9)
Positive functional study 1825 (23.5) 1630 (23.5) 79 (21.7) 116 (24.1)
Ischemic heart disease 522 (6.7) 465 (6.7) 30 (8.2) 27 (5.6)
Chest pain 5217 (67.1) 4641 (66.9) 246 (67.6) 330 (68.5)
Acute coronary syndrome 504 (6.5) 433 (6.2) 33 (9.1) 38 (7.9)
Post-angiography revascularization, n (%) 0.08
None 4878 (62.7) 4335 (62.5) 225 (61.8) 318 (66)
PCI 1831 (23.5) 1634 (23.6) 100 (27.5) 97 (20.1)
CABG 1071 (13.8) 965 (13.9) 39 (10.7) 67 (13.9)
Coronary artery disease (CAD) status 0.09
No CAD 1377 (17.7) 1242 (17.9) 55 (15.1) 80 (16.6)
Non-obstructive CAD 1566 (20.1) 1392 (20.1) 62 (17) 112 (23.2)
Obstructive CAD 4837 (62.2) 4300 (62) 247 (67.9) 290 (60.2)
ACE inhibitor/ARB < 0.0001
Not prescribed 2339 (30.1) 2127 (30.7) 103 (28.3) 109 (22.6)
Prescribed 5441 (69.9) 4807 (69.3) 261 (71.7) 373 (77.4)
PDC < 0.8 1164 (21.4) 985 (20.5) 65 (24.9) 114 (30.6)
PDC ≥ 0.8 4277 (78.6) 3822 (79.5) 196 (75.1) 259 (69.4)
Beta-blocker 0.02
Not prescribed 1569 (20.2) 1423 (20.5) 69 (19.0) 77 (16.0)
Prescribed 6211 (79.8) 5511 (79.5) 295 (81.0) 405 (84.0)
PDC < 0.8 1090 (17.5) 945 (17.1) 61 (20.7) 84 (20.7)
PDC ≥ 0.8 5121 (82.5) 4566 (82.9) 234 (79.3) 321 (79.3)
Statins 0.0001
Not prescribed 967 (12.4) 877 (12.6) 43 (11.8) 47 (9.8)
Prescribed 6813 (87.6) 6057 (87.4) 321 (88.2) 435 (90.2)
PDC < 0.8 1567 (23.0) 1345 (22.2) 94 (29.3) 128 (29.4)
PDC ≥ 0.8 5246 (77.0) 4712 (77.8) 227 (70.7) 307 (70.6)
Abbreviations: CAD coronary artery disease, BMI body mass index, PAD peripheral artery disease, HF heart failure, COPD chronic obstructive
pulmonary disease, CKD chronic kidney disease, PTSD post-traumatic stress disorder, ACE inhibitor angiotensin-converting enzyme inhibitor, ARB
angiotensin receptor blocker, Statin HMG-CoA-reductase inhibitor, HbA1c hemoglobin A1c, PDC proportion of days covered
adherence to ACEi/ARB, beta-blocker, statin, and sulfonyl-
urea, but did not differ across levels of metformin adherence
(Table S13). There were too few mortality events to compare
the associations of adherence with mortality between HbA1c
trajectory classes.
DISCUSSION
In this study, we found three glycemic control trajectories in
diabetes patients without and with objectively determined
CAD receiving real-world clinical care. Two of the trajectory
classes exhibited a qualitative inflection point at or near the
Fig. 1 Hemoglobin A1c trajectory classes in individuals with diabetes
who undergo cardiac catheterization. Predicted and observed
longitudinal hemoglobin A1c (HbA1c) trajectories plotted over time
from a three-class joint latent class mixed model that includes the
last HbA1c value preceding cardiac catheterization (day 0) and all
measurements during up to two 2 years of follow-up. Predicted
values for class members indicated with solid dots, observed values
indicated with solid lines, and 95% confidence intervals indicated
with dashed lines.
Fig. 2 Predicted survival probability over 2 years after cardiac
catheterization for individuals in three hemoglobin A1c trajectory
classes. Predicted survival probability based on multivariable joint
latent class mixed models, adjusted for demographic and clinical
covariates, in the full study cohort (a) and in those diagnosed with
obstructive coronary artery disease at the time of cardiac catheter-
ization (b).




HbA1c < 7% (53 mmol/mol) Ref –
7% ≤HbA1c < 9% (53–74 mmol/mol) 1.01 (0.96, 1.06) 0.81
HbA1c ≥ 9% (≥ 75 mmol/mol) 1.02 (0.95, 1.10) 0.58
*Type 3 Wald test P = 0.85 for difference across 3 baseline HbA1c groups
Fig. 3 Diabetes medication distribution over two years of follow-up
across HbA1c trajectory classes. Proportion of participants in
HbA1c trajectory Class A, B, and C on 0, 1, 2, or > 2 diabetes
medications at baseline, 6, 12, and 24 months after cardiac
catheterization (A). Proportion of participants in each HbA1c
trajectory class prescribed no diabetes medications, insulin, metfor-
min, sulfonylurea, or other diabetes medication at baseline, 6, 12,
and 24 months after cardiac catheterization (B).
time of cardiac catheterization, suggesting the clinical event
may have impacted diabetes self-management or treatment in
a subset of patients in this cohort. Relative to the most com-
mon trajectory—maintaining a stable, low HbA1c after
catheterization—the trajectory with intermediate baseline
HbA1c and gradually increasing HbA1c after catheterization
was associated with higher short-term mortality. In contrast, a
trajectory characterized by high baseline HbA1c but declining
after catheterization did not have higher mortality than the low,
stable HbA1c trajectory. Notably, HbA1c at the time of cardiac
catheterization was not associated with mortality.
Our analysis suggests that glycemic control trajectories may
be more informative for predicting clinical outcomes than a
single HbA1c measurement at the time of cardiac catheteriza-
tion and CAD diagnosis. We have previously shown that
HbA1c examined as a time-varying predictor after cardiac
catheterization was associated with 2-year all-cause mortality
only for HbA1c values < 6% relative to a reference of 6.5 <
HbA1c ≤ 7%.27 The joint latent classmodeling approach taken
here complements the prior work by examining associations of
time-varying patterns in HbA1c, rather than individual values,
with mortality. In other words, two individuals with the same
HbA1c value measured several months after cardiac catheter-
ization may have distinguishable risk of mortality when that
single value is placed in the context of an HbA1c trajectory
based on serial measurements.
We found relatively minor differences in descriptive char-
acteristics, if any, between the patients in each HbA1c trajec-
tory class, suggesting that HbA1c trajectory may not be easy
to predict at the time of coronary angiography based on the
variables we examined. While the mortality differences be-
tween trajectory classes were small, the association between
trajectories and a clinically important outcome lends credence
to this approach. In fact, most EHR systems are already able to
present longitudinal HbA1c measurements to clinical pro-
viders, so adding HbA1c trajectories to clinical dashboards
used to inform diabetes care may be an easily adopted change.
Prior trajectory analyses applied to HbA1c in diabetes pa-
tients focused on long-term glycemic control trajectories, their
predictors, and their associations with subsequent rather than
contemporaneous clinical outcomes.22–24 The prior work,
therefore, describes how glycemic control over the natural
history of diabetes predicts future clinical outcomes (“legacy
effect” of glycemia28, 29) and identifies predictors of specific
glycemic control trajectories. To further understand associa-
tions of the natural history of glycemic control in diabetes
patients with clinical outcomes, joint latent class mixed
models could be applied to individuals with similar baseline
HbA1c values that diverge over time. However, our goal in
this study was to describe the glycemic control trajectories
observed after an important clinical event, the diagnosis of
CAD, and to evaluate whether serial HbA1c measurements
from real-world clinical care could inform diabetes care con-
temporaneously. Indeed, our data suggest that serial HbA1c
measurements occurring at or near the frequency
recommended by the ADA (every 6 months)1, 11 could be
used to determine whether individuals with recently diagnosed
CAD exhibit high-risk glycemic control trajectories,
complementing prior work evaluating long-term HbA1c tra-
jectories and individual time-varying HbA1c measurements.
The exploratory analysis of diabetes treatments prescribed
across HbA1c trajectory classes suggests that differences in
medication prescribing alone are unlikely to explain the dif-
ferent glycemic control trajectories. Class A individuals were
more likely to be on no diabetes medications and less likely to
be on insulin at baseline, suggesting that differences in diabe-
tes severity at baseline could partly explain better outcomes in
this group. Despite divergent HbA1c trajectories, patients in
classes B and C were similar in treatment at baseline and
during follow-up, consistent with providers basing treatment
decisions on single HbA1c values rather than HbA1c trajec-
tories. Prior studies have described higher rates of diabetes
treatment intensification after acute myocardial infarction in
individuals with higher HbA1c,30, 31 and we observed a sim-
ilar increase in treatment in trajectory class B and C individ-
uals compared to those in class A.
It is important to point out that our results suggest that
HbA1c trajectories may help classify diabetes patients into
different short-term mortality risk categories, but do not imply
a causal relationship between the trajectories and mortality.
That is, the HbA1c trajectory itself may not be a useful target
of a clinical intervention yet may be an indicator that other
intervenable factors—e.g., medication adherence or other
diabetes-related health behaviors—may need attention. More-
over, our analysis did not comprehensively evaluate variables
that may be associated with both HbA1c trajectory and mor-
tality, for example, socioeconomic factors such as housing and
income stability. Future work is needed to better define the
causes and consequences of the different trajectories observed
in this study. The exploratory evaluation of medication adher-
ence performed in this study confirms crude associations of
adherence with 2-year mortality and suggests variation in
adherence across trajectory classes. Recent work in a similar
patient population found that HbA1c at the time of acute
myocardial infarction was correlated with adherence to
cardioprotective medications in the following year,32 provid-
ing a plausible link between the rising HbA1c in class C
individuals and higher short-term mortality. Evaluating time-
varying medication adherence as a predictor of trajectory
classes and as a mediator of their associations with mortality
would be computationally challenging in the framework of the
joint modeling approach used in this study and will be evalu-
ated in future research.
Our study has several limitations. First, we cannot conclude
causality between glycemic control trajectories and short-term
mortality, nor can we infer that any patient characteristics
causally determine trajectory class membership. Second, the
trajectory models are inherently subjective as they depend on
model fit statistics and investigator-determined criteria for
model selection. Third, the use of a clinical registry limited
to individuals who had undergone cardiac catheterization
makes our study susceptible to selection bias. That is, individ-
uals who have undergone coronary angiography may not
represent the general population of diabetes patients without
and with CAD. Finally, our study population is predominantly
male, limiting generalizability of the results.
Our study also has several clinically relevant implications.
By focusing on short-term mortality, our study evaluated an
important clinical outcome in a high-risk population at a
vulnerable time—patients with diabetes in the first 2 years
after CAD diagnosis. We provide observational evidence that
HbA1c trajectories may be informative for classifying risk in
diabetes patients, possibly more so than the last available
HbA1c measurement upon which most guidelines currently
base diabetes management recommendations. In the current
era of near-universal adoption of electronic health records and
interest in the “learning healthcare system”,33 computational
tools or dashboards that report biomarker or risk factor trajec-
tories in addition to the last available measurement warrant
further study to determine if they can help improve outcomes.
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